Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce the availability of VERZENIO™ (abemaciclib). VERZENIO is indicated for the treatment of estrogen and/or progesterone hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (mBC): in combination with an aromatase inhibitor for postmenopausal women as initial endocrine-based therapy; in combination with fulvestrant for women with disease progression following endocrine therapy; and as a single agent for women with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
VERZENIO is a cyclin-dependent kinase (CDK) 4 & 6 inhibitor. The recommended dose of VERZENIO in combination with endocrine therapy (i.e. anastrozole, letrozole, fulvestrant) is 150 mg orally twice daily, and as monotherapy is 200 mg, continued until disease progression or unacceptable toxicity. VERZENIO is available in four tablet strengths (200 mg, 150 mg, 100 mg, and 50 mg).
“When a new medication is approved to effectively treat breast cancer, it brings additional options to Canadian women living with metastatic breast cancer”, says Cathy Ammendolea, Chair of the Board of Directors for the Canadian Breast Cancer Network (CBCN). “Having more treatment options for women living with advanced breast cancer means we continue to move in a direction that may enable these women to live their lives to the fullest.”
“Targeted therapies like abemaciclib, may help patients whose breast cancer presents with certain disease characteristics that confer a less favorable prognosis,” says
Dr. Christine Brezden-Masley, Medical Oncologist, Medical Director of Cancer Services, Mount Sinai Hospital in Toronto, Ontario. “Because breast cancers are as diverse as the women who have them, and advanced disease can be a labyrinth of tumour sites and presentation, mBC remains a challenging disease to treat. By disrupting the pathway that leads cancer cells to grow and divide, abemaciclib either alone, or in combination with endocrine therapy, can manage metastatic disease for some by delaying disease progression.”